Search
Search Results
-
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial....
-
Learnings about Aβ from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer’s disease immunotherapeutics
Despite ongoing debate, the amyloid β-protein (Aβ) remains the prime therapeutic target for the treatment of Alzheimer’s disease (AD). However,...
-
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
BackgroundLecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with...
-
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
BackgroundLecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across...
-
Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and neuronal abnormalities. Current therapies...
-
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta
BackgroundAmyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer’s disease (AD). A number of monoclonal...
-
SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease
BackgroundAlzheimer’s disease (AD) immunotherapy with antibodies targeting amyloid-β (Aβ) has been extensively explored in clinical trials. The aim...
-
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
BackgroundLecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain...
-
The Amyloid Cascade Hypothesis Has to Deliver, Finally
The Alzheimer’s field has been intensively searching for a therapy, especially in the last 30 years, while the number of affected individuals has...
-
Cognitive Deficits and Alzheimer’s Disease-Like Pathologies in the Aged Chinese Tree Shrew
Alzheimer’s disease (AD) is the most common chronic progressive neurodegenerative disease in the elderly. It has an increasing prevalence and a...
-
Role of Immunotherapy in Ameliorating Proteopathic Dementia
Dementia is a syndrome that marks a significant cognitive decline with an estimated 50 million populations being affected by this globally and...
-
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to...
-
Nanotechnology and Nature-Sourced Ingredients for Tackling Neurodegenerative Diseases
Neurodegenerative diseases (NDDs) pose a significant and pressing societal challenge in the twenty-first century, demanding immediate attention....
-
Immunotherapy: An Approach to Treat Alzheimer’s Disease and Autism Spectrum Disorder
Since the late 1980s, Alzheimer’s disease (AD) and autism spectrum disorder (ASD) had spread rapidly, and still, it persists in growing numbers....
-
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Alzheimer’s disease (AD) is a priority health problem in developed countries with a high cost to society. Approximately 20% of direct costs are...
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
BackgroundRecruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically...
-
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia
Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other...
-
Application of CRISPR/Cas9 System in the Treatment of Alzheimer’s Disease and Neurodegenerative Diseases
Alzheimer’s, Parkinson’s, and Huntington’s are some of the most common neurological disorders, which affect millions of people worldwide. Although...
-
Cryo-EM of Aβ fibrils from mouse models find tg-APPArcSwe fibrils resemble those found in patients with sporadic Alzheimer’s disease
The use of transgenic mice displaying amyloid-β (Aβ) brain pathology has been essential for the preclinical assessment of new treatment strategies...
